Fulcrum Therapeutics (FULC) Cash from Investing Activities (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Cash from Investing Activities data on file, last reported at -$128.2 million in Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at -$128.2 million, down 16400.64% year-over-year; the trailing twelve-month figure through Mar 2026 was -$96.7 million (down 1348.9% YoY), and the FY2025 annual result was $30.7 million, down 4.69% from the prior year.
• Cash from Investing Activities retreated to -$128.2 million in Q1 2026 per FULC's latest filing, from -$1.0 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $38.1 million in Q1 2024 and troughed at -$128.2 million in Q1 2026.
• A 5-year average of -$5.3 million and a median of $4.4 million in 2024 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2023 and 2026: Cash from Investing Activities surged 934.58% in 2023, then tumbled 16400.64% in 2026.
• A 5-year view of Cash from Investing Activities shows it stood at -$36.4 million in 2022, then soared by 150.48% to $18.4 million in 2023, then sank by 87.69% to $2.3 million in 2024, then tumbled by 146.42% to -$1.0 million in 2025, then plunged by 12122.12% to -$128.2 million in 2026.
• Business Quant data shows FULC's Cash from Investing Activities at -$128.2 million in Q1 2026, -$1.0 million in Q4 2025, and $18.6 million in Q3 2025.